Anima Biotech is advancing Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against many diseases.
With novel biology that monitors the translation of proteins and proprietary cloud-based software, we identify drug candidates that modulate a target protein’s production.
We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets.
Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.
With novel biology that monitors the translation of proteins and proprietary cloud-based software, we identify drug candidates that modulate a target protein’s production.
We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets.
Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
Collagen I translation inhibitors
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
